Market Analysis Report Oncology Biosimilars Market 2019 | Seite 2

Increasing number of alliances for development of biosimilar is expected to propel the growth of
oncology biosimilars market over the forecast period. Oncology biosimilars are the versions of biologics
which are manufactured by numerous companies and has been officially approved for cancer treatment.
They are cost-effective and efficient as the original biologic. Adoption of oncology biosimilars for the
treatment of cancer is boosting growth of the global oncology biosimilars market.
Oncology Biosimilars Market Covers the Table of Contents With Segments, Key Players And Region.
Based on Product Type, Oncology Biosimilars Market is sub segmented into mAb, Immunomodulators,
Hematopoietic Agents, G-CSF. On the Basis of Application, Market is sub segmented into Retail
Pharmacies, Hospital Pharmacy, Online Pharmacy.
Major Players profiled in the Oncology Biosimilars Market report incorporate: Celltrion, Biocon, Dr.
Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva
Pharmaceutical, Apotex, BIOCAD
Top Industry for Oncology Biosimilars Market News
Pfizer
Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved
TRAZIMERA (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab),1 for the treatment of human
epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing
metastatic gastric or gastroesophageal junction adenocarcinoma.
The FDA approval was based on review of a comprehensive data package, which demonstrated a high
degree of similarity between TRAZIMERA and the originator product. This includes results from the
REFLECTIONS B327-02 clinical comparative study that was recently published in the British Journal of
Cancer, which showed clinical equivalence, finding a high degree of similarity and no clinically
meaningful differences between TRAZIMERA and the originator product in patients with first line HER2
overexpressing metastatic breast cancer.
Sandoz International
Sandoz, a Novartis division and a global leader in biosimilars, today announced that it has entered into
an agreement to commercialize a proposed trastuzumab biosimilar. This medicine is currently in Phase
III clinical development for treatment of human epidermal growth factor receptor 2 positive (HER2+)
breast and specific gastric cancer tumors.
The agreement between Sandoz and EirGenix, Inc, a biotechnology manufacturing and development
company that aspires to provide high-quality medicines for individuals and society, aims to bring to
market a proposed biosimilar trastuzumab. EirGenix will maintain responsibility for development and
manufacturing, and Sandoz has the right to commercialize the medicine upon approval in all markets
excluding China and Taiwan.